New analysis shows DAYTRANA offered ADHD symptom control for...(ad a 23 percent change on the scale (as ...),Health

On the CGI-I scale, clinicians rated 83 percent of boys and girls improved or very much improved at the end of the study compared to week one. Additionally, the PGA rating scale showed that 78 percent of boys and girls improved or very much improved at the end of the study compared to week one. The results in both the CGI-I and PGA scale were comparable between boys and girls.

Dr. Findling added, These positive findings, along with previously presented research, reinforces that the ADHD patch is an important treatment option for children, especially those who may benefit from an ADHD medication that can accommodate their changing daily needs.

DAYTRANA is the first and only non-oral medication for treating ADHD in children aged 6 to 12 years. Parents can adjust the wear time up to 9 hours under the physicians advice to accommodate for their childs varying weekdays, weekend and vacation schedules. DAYTRANA is available in four dosage strengths 10 mg, 15 mg, 20 mg and 30 mg all designed for once-daily use.

While this study evaluated the safety and effectiveness of DAYTRANA for up to 12 months, DAYTRANA has not been studied versus placebo for longer than 7 weeks. Physicians, who prescribe DAYTRANA for long-term use, should periodically re-evaluate patients to assess the usefulness of DAYTRANA for the individual patient.

'/>"/>